BOWFLEX INC.: Nasdaq/NYSE listing notice — Nautilus receives NYSE non-compliance notice for share price below $1.00

BOWFLEX INC.

NYSE notified Nautilus on Sept 21, 2023, that average closing price was below $1.00 over 30 consecutive trading days.
Company has six months from notice date to cure the deficiency; no immediate delisting impact.
Intends to notify NYSE of intent to cure within 10 business days.
To regain compliance, closing price must be at least $1.00 on last trading day of a month and average at least $1.00 over prior 30 days.
If a cure requires shareholder approval, price condition may be deemed cured if price exceeds $1.00 for at least 30 trading days following shareholder meeting.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BOWFLEX INC. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

Exchange: nyse
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 802.01C

Exact text from the filing

September 21, 2023, Nautilus, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the Company was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period (the “minimum share price requirement”). The Notice has no immediate impact on the listing of the Common Stock on the NYSE, subject to the Company’s complia

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001078207-23-000123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.